


Deciphering Radical Transport in the Large Subunit of Class I Ribonucleotide Reductase

Patrick G. Holder, Arturo A. Pizano, Bryce L. Anderson, JoAnne Stubbe, and Daniel G. Nocera*

Department of Chemistry, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States

S Supporting Information

ABSTRACT: Incorporation of 2,3,6-trifluorotyrosine (F₃Y) and a rhenium bipyridine ([Re]) photooxidant into a peptide corresponding to the C-terminus of the β protein (β C19) of *Escherichia coli* ribonucleotide reductase (RNR) allows for the temporal monitoring of radical transport into the α 2 subunit of RNR. Injection of the photogenerated F₃Y radical from the [Re]-F₃Y- β C19 peptide into the surface accessible Y731 of the α 2 subunit is only possible when the second Y730 is present. With the Y-Y established, radical transport occurs with a rate constant of $3 \times 10^5 \text{ s}^{-1}$. Point mutations that disrupt the Y-Y dyad shut down radical transport. The ability to obviate radical transport by disrupting the hydrogen bonding network of the amino acids composing the colinear proton-coupled electron transfer pathway in α 2 suggests a finely tuned evolutionary adaptation of RNR to control the transport of radicals in this enzyme.



INTRODUCTION

Ribonucleotide reductases (RNR) are the keystone of DNA biosynthesis in all organisms. They remove the 2' hydroxyl from nucleoside diphosphates (NDPs) to generate deoxynucleoside diphosphates (dNDPs).¹ The *Escherichia coli* class Ia RNR is composed of two subunits— α 2 and β 2—that form an active α 2: β 2 complex when in the presence of substrate (S) and effectors (E). The α 2 subunit houses the catalytic cysteine (C439) as well as two allosteric sites that control both substrate specificity and turnover rate. β 2 stores a diiron-centered tyrosyl radical cofactor (Fe₂-•Y122) that is essential for catalysis in α 2. The binding of substrate and effector enhances intersubunit interactions and triggers Fe₂-•Y122-mediated C439 oxidation in α 2 from a distance of 35 Å. Whereas the mechanism of catalysis² by the enzyme is understood, the basis for S/E-mediated conformational change³ and the attendant dynamic transport of the radical through the protein to the active site are yet to be unraveled. This report focuses on the use of a phototriggered β 2 surrogate to monitor, for the first time, the kinetics of proton-coupled electron transfer (PCET) within α 2.

At 35 Å separation, the vanishingly small overlap of the amino acid wave functions precludes a single-step superexchange mechanism.⁴ Accordingly, current models^{4–7} posit a stepwise translation of the radical across the two proteins: •Y122 \rightleftharpoons [W48?] \rightleftharpoons Y356 in β 2 to Y731 \rightleftharpoons Y730 \rightleftharpoons C439 in α 2.

This proposed pathway is an outgrowth of a docking model between α 2 and β 2 whose structures were determined crystallographically.^{8,9} It is bolstered by observations that the enzyme is inactive when point mutations into residues that cannot be oxidized are made on the pathway.^{10–12} Measurement of radical transport along the pathway is masked by rate-

limiting conformational changes caused by S/E binding to α 2 prior to rapid radical propagation and nucleoside reduction.

To permit investigation of this radical transport pathway, methods have been developed to site-specifically incorporate unnatural amino acids in place of each proposed tyrosine in the pathway. This allows for enzyme turnover to be monitored as a function of modulated phenolic pK_a and reduction potential.^{13,14} Studies using the more easily oxidized 3-amino-tyrosine (NH₂Y) in place of Y356 (β 2), Y730 (α 2), and Y731 (α 2) establish the conformational gating and its complexity,^{13–16} and PELDOR spectroscopy of these protein mutants establishes long-range radical initiation and more generally the validity of the docking model.¹⁷ Incorporation of 3-NO₂Y, a strong oxidant, at position 122 in β 2 has fortuitously resulted in uncoupling of conformational gating.¹⁸ Millisecond time scale kinetics experiments have revealed that 3-NO₂Y122• in the presence of α 2, CDP (S) and ATP (E) is rapidly reduced to the 3-NO₂Y phenolate concomitant with dCDP formation and generation of a mixture of three tyrosyl radicals at 356, 731, and 730. The baseline catalytic turnover of the wild-type α 2: β 2 complex is 2–10 s⁻¹.⁴ The observed rate constant in these mutants is 100–300 s⁻¹, or 10–150 times faster than wild-type turnover.¹⁸ These studies provide the direct observation of pathway radicals and start to define their relative redox potentials.¹⁹

The PCET kinetics among these pathway radicals may be isolated with photoRNRs. In this construct, a short peptide (Y- β C19) has been employed in place of full-length β 2.^{20,21} This peptide contains the C-terminal 20 amino acids of the β

Received: September 30, 2011

Published: November 28, 2011

protein (β C20), including both the determinant for binding β 2 to α 2²² and Y356 in β 2, which facilitates radical transport at the α 2: β 2 interface.³ By appending a photooxidant (PO) to this peptide (PO–Y– β C19), the equivalent of \bullet Y356 (\bullet Y– β C19) can be photochemically generated. Photoinitiated substrate turnover can be observed for the PO–Y– β C19: α 2 construct upon illumination.^{21,23} For instance, installation of 3,5-difluorotyrosine in PO–Y– β C19 can generate a radical that is able to generate dNDPs in the absence of β 2.²¹ However, to date, measurement of electron transfer between Y356 and the transport pathway in α 2 has not been achieved, and more generally, the physiologically relevant^{24,25} dynamic transport of a radical in any enzyme has yet to be observed.

In this work, we transiently generate an unnatural fluorotyrosyl radical with the rhenium PO in the presence of four mutants of the catalytic subunit of RNR shown in Figure 1. We temporally observe the radical as it propagates into α 2 and measure the radical injection rate into the $Y731 \rightleftharpoons Y730 \rightleftharpoons C439$ pathway of α 2.




Figure 1. Photoactive peptide [Re]–F₃Y– β C19 displays a fluorotyrosyl radical at the equivalent position to Y356 in β 2. The method of radical transport into α 2 from Y356 \rightarrow Y731 \rightarrow Y730 \rightarrow C439 is deciphered by monitoring the radical in the presence of the stop mutants Y731F- α 2, Y730F- α 2, C439S- α 2 as well as the wt- α 2.

EXPERIMENTAL SECTION

Materials. The β C19 peptide was synthesized on resin by Pi Proteomics (Huntsville, AL; piproteomics.com) by starting with Fmoc-L-Leu-PEG-PS resin (Applied Biosystems, 180 μ mol/g), and using our previously described protocol.²⁶ 4-methyl-4'-carboxyl-2,2'-bipyridine, RNR subunit β 2 (1.2 \bullet Y122/ β 2, 5,400 nmol/min/mg), *E. coli* thioredoxin (TR, 40 U/mg), *E. coli* thioredoxin reductase (TRR, 1400 U/mg), [Re]–Y– β C19, and hydroxybenzotriazole (HOBT) were available from previous studies. Protected Fmoc-2,3,6-trifluorotyrosine was prepared as previously reported.^{13,27} [5-³H]-CDP was purchased from ViTrax (Placentia, CA). Other chemicals were of reagent grade or higher, sourced commercially, and used as received. These compounds, and their abbreviations, are listed in the Supporting Information.

Cell Stocks, Plasmids and Primers. *E. coli* BL21(DE3) cells were purchased from Novagen. *E. coli* XL-10 Gold cells were purchased from Agilent (formerly Stratagene). The pET-*nrdA*(wt) plasmid encoding for N-terminally (His)₆-tagged wt RNR protein α was available from a previous study.¹⁶ Primers used in site-directed mutagenesis were purchased in purified form as a custom synthesis from Invitrogen.

pET-*nrdA*(wt) Site-Directed Mutagenesis and Transformation. Site-directed mutagenesis (SDM) was carried out with the Quickchange Kit from Stratagene. Each mutant was generated by amplifying the template, pET-*nrdA*(wt), with Pfu Ultra II polymerase in the presence of the forward and reverse primers whose sequences are listed in the Supporting Information. Amplification of pET-*nrdA* mutant plasmids was accomplished by transformation of SDM reaction mixtures into XL-10 gold cells by following the manufacturer's instructions. Plasmids were isolated using a Miniprep kit from Qiagen, eluting the final plasmid with di-H₂O. DNA sequencing was performed by the MIT Biopolymers Lab. pET-*nrdA* transformation into BL21(DE3) cells was completed by following the manufacturer's instructions.

NrdA Mutant Expression. A solution of 75 μ L of the SOC media BL21(DE3) transformant was spread aseptically onto an LB-agar plate containing kanamycin (Km) at 50 μ g/mL. The plate was then incubated overnight at 37 $^{\circ}$ C. After 14 h of growth, the plate showed well-dispersed individual colonies. One colony from the plate was picked, which was incubated at 37 $^{\circ}$ C in 5 mL of LB media containing 50 μ g/mL Km on a rotating tumbler until saturated (10–20 h). One mL of this culture was then diluted into 100 mL of LB-Km media in a 500 mL Erlenmeyer flask and incubated at 37 $^{\circ}$ C while shaking at 220 rpm for 12 h. 50 mL of this saturated culture was then diluted into 10 L of LB-Km media in a Beckman Scientific fermentor. The temperature was set to 37 $^{\circ}$ C with air sparging at 10 L/h and stirring at 500 rpm. After 2.5 h of growth ($OD_{600} = 0.67$), protein production was induced by adding 10 mL of 1 M IPTG, giving 1 mM in solution. Growth continued for 4 h, at which point the cells were harvested by centrifugation (10 min, 7,000 \times g), flash frozen at 77 K, and stored at –80 $^{\circ}$ C. Typical yield was 3–5 g/L wet cell paste.

(His)₆- α 2 Purifications. "Lysis buffer" consisted of 50 mM Tris (pH 7.6 at 4 $^{\circ}$ C) containing 5% glycerol, 1 mM PMSF, 10 mM imidazole and 10 mM DTT. The solid DTT and PMSF (0.2 M in EtOH) were added just before use. The details for a single purification of the Y730F mutant follow, and the other mutants were purified in the same manner. Frozen cell pellet (7.4 g) was thawed on ice with 5 mL of lysis buffer per gram of pellet (35 mL total). The suspension was then prepared for lysis with several passes through a Teflon/glass homogenizer. The cells were then lysed with a single pass through a SLM-Aminco French pressure cell (with the cell and its fittings precooled on ice) at between 16,000 and 18,000 psi. The resulting suspension was then centrifuged (25,000 \times g, 30 min). The pellet was discarded and the supernatant was poured into a stirring solution of 0.2 vol equiv (16 mL) of 6% w/v streptomycin sulfate at 4 $^{\circ}$ C. The solution was stirred for 30 min at 4 $^{\circ}$ C and centrifuged (25,000 \times g, 30 min). The supernatant was then loaded onto a Ni-NTA superflow (Qiagen) column (25 mL), which had been equilibrated with lysis buffer containing 500 mM NaCl. The column was then washed with

10 CV (250 mL) of lysis buffer to remove cellular proteins, and collected in five 50 mL fractions. The protein was then eluted with a 500 mL linear gradient of 10–300 mM imidazole in lysis buffer and collected in 1.5 min (12 mL) fractions. The fractions containing only α protein (by SDS-PAGE) were pooled and concentrated to 30 mL while stirring in an Amicon pressure concentrator fitted with a 30 kD MWCO membrane at 50 psi N_2 . The solution was then loaded onto a 200 mL G-25 column and eluted with "spectroscopy buffer" (50 mM sodium borate (pH 8.3 at 23 °C), containing 15 mM $MgSO_4$ and 5% v/v glycerol). The eluent was collected in 3 min (10 mL) fractions. Those fractions containing protein, as judged by the Bradford assay, were pooled and concentrated in 30 kD MWCO centrifugal concentrators. Final purity was determined by SDS-PAGE (Figure




Figure 2. Purification and activity of $\alpha 2$ mutants. (a) SDS-PAGE of each mutant after purification indicates a monomer molecular weight at the expected migration (85 kD). (b) Quantification of the gel lanes in (a) by integrating the band density indicates that >98% of the protein in solution is $\alpha 2$ for each mutant prepared. (c) Activity of each enzyme quantified by counting turnover of [3H]-labeled CDP.

2a,b). Final concentration was determined with the known ϵ_{278} of $0.189 \mu M^{-1} cm^{-1}$.²⁷ Activity measurements were performed as previously described (Figure 2c).¹⁶

Synthesis of $Re(I)(CO)_3(CN)(Mebpy-COO-PFP)$ ([Re]-OPFP). The synthesis of $Re(I)(CO)_3(CN)(Mebpy-COOH)$ ([Re]-COOH) has been previously described.²¹ It was determined that the coupling yields of the rhenium carboxylate to the *N*-terminus of the peptide were low under previously reported HATU coupling conditions. As such, the [Re]-COOH was preactivated as a pentafluorophenyl ester. To do so, [Re]-COOH (235 mg, 0.46 mmol, 1 equiv.) was diluted with 2.6 mL DCM and 75 μL DIPEA. The solution was transferred to a 25 mL round-bottom flask under a nitrogen atmosphere, and the vial used to dissolve the carboxylate was washed with an additional 2 mL DCM and 50 μL DIPEA and transferred to the reaction flask. The flask headspace was purged with N_2 and then PFP-TFA (258 mg, 0.92 mmol, 158 μL , 2 equiv) was added dropwise via syringe. The solution was stirred magnetically for 2 h, at which point an additional 1 equiv of PFP-TFA was added and the reaction stirred 90 min more. The reaction was monitored by TLC viewed in 4:1 DCM:EtOAc. Upon consumption of the baseline starting material determined by TLC, the reaction solution was condensed under reduced pressure. The product was purified by flash chromatography on silica gel (2 \times 15 cm). The product was loaded onto the column in DCM, and washed with DCM to elute a pale yellow band ($R_f = 0.9$) corresponding to hydrolyzed

pentafluorophenol. This band was discarded. The bright orange product band was then eluted with 3:1 DCM:EtOAc and collected in 10 mL fractions. Those showing product by UV illumination of TLC spots were pooled, condensed under reduced pressure, and dried in vacuo. Yield 221 mg (71%, bright red-orange solid). 1H NMR (400 MHz, $CDCl_3$, 7.26): δ 2.65 (s, 3H, bpy- CH_3), 7.43 (dd, 1H, $J = 5.6, 0.8$, bpy- H), 8.17 (dd, 1H, $J = 1.6, 6$, bpy- H), 8.23 (s, 1H, bpy- H), 8.85 (d, 1H, $J = 0.8$, bpy- H), 8.89 (d, 1H, $J = 5.6$, bpy- H), 9.31 (d, 1H, $J = 6$, bpy- H). ^{13}C NMR (400 MHz, $CDCl_3$, 77.00): 21.6 (bpy- CH_3), 122.99 (bpy), 125.00 (bpy), 126.50 (bpy), 129.09 (bpy), 136.51 (bpy), 143.61 (bpy), 151.98 (bpy), 153.08 (bpy), 154.21 (bpy), 154.72 (PFP-C-F), 157.73 (PFP-C-F), 159.59 (PFP-C-F), 190.07 (-O-(C=O)-Ar, ester), 194.59 (Re-CO), 194.92 (Re-CN). HPLC: 99%, 6.6 min (isocratic 1:1 MeCN:H $_2$ O w/0.1% TFA).

Synthesis of $(N-Fmoc)-((2,3,6-trifluoro)-tyrosyl)-\beta C19$; $\beta C19 = LVGQIDSEVDTDDLNSFQL$. The as-received $\beta C19$ resin (126 $\mu mol/g$ for the protected peptide, 1 equiv, 992 mg resin) was added to a 20 mL econopac column (Bio-Rad). To this was added 10 mL of deblocking solution (20% v/v piperidine/DMF containing 0.1 M HOBT). The column was capped and vortexed for 10 min at room temperature. The solution was drained, and the deblocking was repeated twice more. The resin was then washed with DMF (5 \times 10 mL for 60 s each) and DCM (3 \times 10 mL for 60 s each). To the column was then added the reaction solution, including (*N*-Fmoc)-2,3,6-trifluorotyrosine (343 mg, 75 mM, 6 equiv), DIPEA (250 μL , 194 mg, 0.15 M, 12 equiv), and DMF (9.75 mL). The reaction was initiated by the addition of HCTU (280 mg, 67.5 mM, 5.4 equiv). The column was vortexed for 2 h at room temperature. The solution was then drained, and the resin was again washed five times with DMF and three times with DCM, as described above. The resin was then dried in the econopac column by pulling on the outlet with vacuum for 2 h. The product was characterized by HPLC and MALDI-MS of a test cleavage of 10 mg of the resin, which confirmed the conjugation. The dry material was stored at 4 °C.

Synthesis of $[Re]-F_3Y-\beta C19$. The Fmoc- $F_3Y-\beta C19$ resin (122 $\mu mol/g$ for the protected peptide, 1 equiv, 1.02 g resin) was added to a 20 mL econopac column (Bio-Rad). To this was added 10 mL of deblocking solution (20% v/v piperidine/DMF containing 0.1 M HOBT). The column was capped and vortexed for 10 min at room temperature. The solution was drained and the deblocking was repeated twice more. The resin was then washed with DMF (5 \times 10 mL for 60 s each) and DCM (3 \times 10 mL for 60 s each). The reaction solution was then added to the column, including [Re]-OPFP (224 mg, 33 mM, 2.6 equiv), HOBT (110 mg, 80 mM, 6.5 equiv), and DMF. The column was vortexed for 90 min at room temperature. The solution was then drained, and the resin was again washed five times with DMF and three times with DCM, as described above. To isolate the peptide from the resin, the econopac was then filled with 10 mL of 95/2.5/2.5 TFA/TIPS/H $_2$ O, capped, and vortexed for 4 h at room temperature. After, the solution was bright yellow and it was drained into a 20 mL scintillation vial and condensed by hand under a stream of N_2 to ~ 2 mL. We note that TFA vapors are noxious and toxic and proper personal protective equipment is imperative. Condensation of TFA by rotary evaporation was avoided. After condensation, the solution was dripped into 45 mL of Et $_2$ O stirring in a 50 mL Falcon tube, which caused immediate precipitation of a bright yellow flocculent solid. The Falcon tube was then capped and incubated at 4 °C for 12 h to encourage further precipitation. The solution was then centrifuged (8,000 \times g, 30 min) and the supernatant discarded. The yellow pellet was then resuspended in 25 mL of Et $_2$ O with vigorous vortexing, and recentrifuged, as before. This wash step was necessary to remove residual TFA, which makes the final peptide difficult to dissolve in dilute basic solutions. The final product was then dried for 12 h under a stream of N_2 . The solid was stored at 4 °C.

Purification of $[Re]-F_3Y-\beta C19$. HPLC analysis of received $\beta C19$ peptide established that further purification was necessary. As such, the final peptide was purified by RP-HPLC. A separation method was first developed on analytical scale. It was found that a 2–17.5% gradient of MeCN in water with 0.1% v/v Et $_3$ N gave adequate separation in 20 min. For semipreparative scale, this same gradient was applied to a 40

min separation time. For each semipreparative run, fractions were collected in 0.5 min increments across the peak of interest. Injections consisted of a 500 μL solution of $\sim 10 \mu\text{mol}$ of crude material dissolved in 5% v/v Et_3N . Fractions containing the desired product, as determined by inline UV and fluorescence, were pooled and condensed in vacuo (50 mTorr). From 16 serial semipreparative runs 30 mg of purified peptide was recovered (8% isolated yield) (Figure 3). HPLC: 98%, 9.5 min (5–15% MeCN in H_2O w/0.1%




Figure 3. Purification, identification, and pK_a of $[\text{Re}]-\text{F}_3\text{Y}-\beta\text{C19}$. (a) HPLC of purified peptide on C-18 resin with a gradient of 5–15% MeCN in 0.1% aqueous Et_3N . (b) UV–vis absorption spectrum of the peak at 9.5 min in (a). (c) HRMS of the peptide in (a). (d) Determination of the pK_a of the phenolic proton by fluorometric titration. Each data point is the intensity at 600 nm for a 5 μM solution in aqueous buffer.

Et_3N over 15 min). MALDI-MS: $[\text{M} - \text{CN}]^+$ e.m. expected 2791.03; found 2790.81.

pK_a of $[\text{Re}]-\text{F}_3\text{Y}-\beta\text{C19}$. The pK_a of the peptide was determined by fluorometric titration (Figure 3). To prepare samples at 5 μM for spectroscopy, 13 μL of a 73 μM stock solution of peptide was diluted into 187 μL of buffer at the following pH values: 5.99, 6.19, 6.41, 6.62, 6.80, 7.00, 7.20, 7.38, 7.55, 7.79, 8.00, 8.20, 8.40, and 8.58. From 5.99 to 7.00 the buffer was 100 mM potassium phosphate. From 7.20 to 8.58 the buffer was 100 mM tris. Each spectrum was recorded by exciting at 315 nm and monitoring from 475–800 nm, in 1 nm increments with 1 s integration per nm. The intensity at 600 nm was then plotted versus pH and fit using Origin software according to a method previously outlined,²⁸ with the assumption that protonation and deprotonation does not occur in the excited state.

K_D of $[\text{Re}]-\text{F}_3\text{Y}-\beta\text{C19}$ and wt- $\alpha 2$. To measure the dissociation of the photopeptide from $\alpha 2$, we used a previously developed²² competitive inhibition assay. The inhibitor was titrated against a solution of wt RNR. In a total volume of 150 μL , each solution contained 100 nM wt- $\alpha 2$, 200 nM wt- $\beta 2$, 200 μM NADPH, 30 μM TR 500 nM TRR, 1 mM CDP, 3 mM ATP, inhibitor peptide, and buffer. The volume of inhibitor peptide (250 μM stock) and buffer (50 mM borate, pH 8.3 with 15 mM MgSO_4 and 5% glycerol) were adjusted so that the peptide was present in the total volume at the following concentrations: 5, 15, 25, 35, and 50 μM .

Transient Spectroscopy and Data Analysis. Solutions for time-resolved spectroscopy were prepared in 1.5 mL Eppendorf tubes at room temperature. Reagents were added to the vial in the following order: first half of buffer, flash quencher (if used), ATP, CDP, peptide, second half of buffer (to encourage mixing), and then protein (if used). Care was taken to avoid using pipet tips for more than one draw of a protein solution. It was found that the second draw of these very concentrated protein solutions in the same pipet tip can lead to small amounts of precipitation on the plastic sidewall. All samples were equilibrated in a water bath at 23 $^\circ\text{C}$ for 3 min before analysis. Unless otherwise noted, “buffer” for all transient spectroscopy samples consisted of 50 mM sodium borate (pH 8.3 at 23 $^\circ\text{C}$) with 15 mM MgSO_4 and 5% v/v glycerol.

Each solution was analyzed while flowing at 10 mL/min through the cuvette. Great care was taken to ensure that no bubbles were in the path length of the cuvette during measurement. In addition, we found that in alkaline solutions, the flash quencher decomposed over time into RuO_2 . At low concentration this side product can slowly deposit on the cell glass, and at high concentrations it rapidly clouds the solution. To alleviate these problems, during the experiment the samples were run continuously through a 13 mm 0.2 μm Supor inline filter (Pall Corp., Port Washington, NY) to remove the byproduct as it is generated. We found that 650 μL was the minimum volume required to flow a sample through the cuvette, pump lines, and inline filter.

Each buffered solution used for time-resolved emission measurements of $[\text{Re}]-\text{F}_3\text{Y}-\beta\text{C19}$ contained in final concentration: 10 μM $[\text{Re}]-\text{F}_3\text{Y}-\beta\text{C19}$, 200 μM $\text{Ru}(\text{NH}_3)_6\text{Cl}_3$, 1 mM CDP, and 3 mM ATP. Each 650 μL buffered solution used for time-resolved emission measurements of $[\text{Re}]-\text{F}_3\text{Y}-\beta\text{C19}$ with $\alpha 2$ variants contained in final concentration: 10 μM $[\text{Re}]-\text{F}_3\text{Y}-\beta\text{C19}$, 20 μM $\alpha 2$ mutant, 200 μM $\text{Ru}(\text{NH}_3)_6\text{Cl}_3$, 1 mM CDP, 3 mM ATP. Each buffered solution used for transient absorption measurements of $[\text{Re}]-\text{F}_3\text{Y}-\beta\text{C19}$ contained in final concentration: 50 μM $[\text{Re}]-\text{F}_3\text{Y}-\beta\text{C19}$, 1 mM $\text{Ru}(\text{NH}_3)_6\text{Cl}_3$, 1 mM CDP, 3 mM ATP. Each 650 μL buffered solution used for transient absorption measurements of $[\text{Re}]-\text{F}_3\text{Y}-\beta\text{C19}$ with $\alpha 2$ variants contained in final concentration: 50 μM $[\text{Re}]-\text{F}_3\text{Y}-\beta\text{C19}$, 100 μM $\alpha 2$ mutant, 1 mM $\text{Ru}(\text{NH}_3)_6\text{Cl}_3$, 1 mM CDP, 3 mM ATP.

The calculation of rate constants for the oxidation of Y by $\bullet\text{F}_3\text{Y}$ was performed using the equation

$$k_{\text{ox}} = k_{\text{on}} - k_{\text{off}} = \frac{1}{\tau_{\text{on}}} - \frac{1}{\tau_{\text{off}}} \quad (1)$$

where k_{on} (τ_{on}) is the rate constant (time constant) for $\bullet\text{F}_3\text{Y}$ decay when the tyrosyl is in the “on” conformation, bound to the protein, and k_{off} (τ_{off}) is the rate constant (time constant) for $\bullet\text{F}_3\text{Y}$ decay when the tyrosyl is in the “off” solvated, conformation. The error of each measurement was propagated using standard methods.²⁹ Transient absorption spectra were an average of three independently collected data sets, corrected for noise inherent to the instrument by fast Fourier transform (FFT) filtering of high frequency noise across the data set. To determine the filter level, a FFT was first performed on the raw data to determine the frequency of signal/noise cutoff. That cutoff filter was then applied to the data set using Origin (see software, SI). Kinetic decay traces were collected from the PMT as intensity values corresponding to a change in voltage. Transient optical density was calculated using,

$$\Delta\text{OD} = -\log\left(\frac{V}{V_0}\right) \quad (2)$$

V_0 was determined by averaging the first 40 data points collected before the 0 time point.

Each decay trace from which a lifetime was calculated was an average of 3–6 individually collected data sets. The standard deviation at each x, y pair was used as the weight term in the fitting. All rate constants were calculated using weighted least-squares regression analysis of Cartesian data pairs in Origin by modulation of variables until the reduced χ^2 ceased changing. The goodness-of-fit parameter

(R^2) was used as a starting point for determining the accuracy of fit; all fits reported are 0.98 or greater R^2 . Subsequently, graphical residual analysis was employed. Those residuals demonstrating significant asymmetry or periodicity with respect to the independent variable were fit again with an additional phase. Error bars were calculated as 67% confidence intervals (one standard deviation). Decays of short (ns) lifetimes were fit using all data points appearing after the time point with maximum amplitude. Decays of radical lifetimes were fit by excluding those data points corresponding to the residual charge-separated state of [Re] by starting at the 1 μ s time point.

RESULTS

Synthesis, Purification and Characterization of Materials. The synthesis of [Re]–F₃Y– β C19 was accomplished on solid phase using established methods. The identity of the modified peptide was confirmed by high-resolution MALDI-TOF MS, its purity by HPLC, and the pK_a of the F₃Y phenol when incorporated within the peptide was found to be 7.1 ± 0.1 ; these data are shown in Figure 3. The observed pK_a of F₃Y in [Re]–F₃Y– β C19 is in accordance with previous measurements of model dipeptides of the F_nY residue.³⁰ We determined the K_D between the $\alpha 2$ subunit and the [Re]–F₃Y– β C19—under the conditions of spectroscopy—to be $9 \pm 1 \mu$ M using a competitive inhibition assay (Figure S1), which agrees with measurements on our previous photoRNR systems.^{21,31} Due to the modest affinity of the peptide for the subunit, the spectroscopic measurements require large amounts of α ; thus, the expression and purification of each $\alpha 2$ (Figure 2) was accomplished on gram scale with hexahistidine affinity chromatography.

[Re]–F₃Y– β C19 Charge-Separated State. Spectroscopic observation of F₃Y radical injection into $\alpha 2$ requires a detailed understanding of all transient spectroscopic features present. The generation of the F₃Y radical was confirmed by comparing the excitation of a peptide that cannot be oxidized, [Re]–F– β C19, to the peptide containing the fluorotyrosine. Photolysis of [Re]–F– β C19 at pH 8.3 generates a [Re^I]* (³MLCT) excited state, which cannot oxidize the adjacent phenylalanine. The [Re^I]* can be monitored by recording the decay of the emission intensity at $\lambda_{max} = 610$ nm; a monoexponential lifetime of 62 ns is observed.³¹ In contrast to [Re]–F– β C19, excitation of [Re]–F₃Y– β C19 at pH 8.3 generates [Re^I]* that decays with biphasic kinetics (Figure S2). The long component (58 ns, 19%) corresponds to [Re^I]* that is unchanged by the proximal F₃Y, while the short component (22 ns, 81%), represents the quenching of [Re^I]* by the deprotonated F₃Y[–]. The decay is biexponential as a result of measuring two chemical species in solution—protonated and deprotonated tyrosine.

Whereas the emission decay of the [Re^I]* can be used to reveal the quenching of the ³MLCT, the photoproducts of the quenching reaction may be captured by transient absorption (TA) spectroscopy. Figure 4 shows the time-resolved spectral features upon excitation of [Re]–F₃Y– β C19 at three different time points. The absorption features for [Re^I]* appear as broad bands at 380 and 480 nm;³¹ the decay of the transient signal at these two TA wavelengths yields decay time constants of 60 ± 2 and 61 ± 2 ns, respectively. In addition, new spectral features corresponding to the bpy^{•–} and the \bullet F₃Y appear in the spectrum at $\lambda_{max} = 525$ and 425 nm, respectively.²¹ The \bullet F₃Y signal decays monoexponentially with a time constant of 68 ns. In contrast, the signal for the bpy^{•–} is best fit to a biexponential as a combination of growth and decay. This complication in the measured TA kinetics arises from the spectral congestion




Figure 4. TA spectra of the charge-separated state [Re(bpy^{•–})]– \bullet F₃Y– β C19 collected 25 ns (top), 75 ns (middle) and 125 ns (bottom) after a 7 ns excitation pulse of laser light, $\lambda_{exc} = 355$ nm. Lifetime decays of the transient spectrum were measured at the four wavelengths indicated by the dashed lines: λ_{det} at 380 and 480 nm correspond to the ³MLCT of [Re^I];³⁰ $\lambda_{det} = 525$ nm is that of bpy^{•–};²¹ and, $\lambda_{det} = 425$ nm is that of \bullet F₃Y. The solution contained 50 μ M [Re]–F₃Y– β C19 with 1 mM CDP, 3 mM ATP, 15 mM MgSO₄, and 5% glycerol in 50 mM sodium borate (pH 8.3).

between the emission of [Re^I]* excited state ($\tau = 22$ ns) and the decay of bpy^{•–} anion over 76 ns. The appearance of signals for both the \bullet F₃Y and the bpy^{•–} anion with the concomitant disappearance of [Re^I]* establishes that the excited state is quenched by deprotonated tyrosine in an intramolecular charge transfer event to result in a charge-separated [Re(bpy^{•–})]– \bullet F₃Y– β C19 intermediate. The duration of this charge-separated state agrees well with previously reported lifetimes for model compounds.³⁰

Generation of a Long-Lived \bullet F₃Y by the Flash-Quench Method. The rapid decay of the charge-separated state (discussed above) on a sub 100 ns time scale precludes faithful measurements of radical injection rates slower than 10^7 s^{–1}. The likelihood for oxidative injection from the \bullet F₃Y radical into $\alpha 2$ increases as the lifetime of the radical increases. The \bullet F₃Y lifetime can be increased by employing the flash-quench method to irreversibly remove the electron from the [Re^I]* excited state by electron transfer to a flash quencher (FQ), Ru(NH₃)₆Cl₃. By removing the electron from the system with the FQ, back electron transfer is averted and the flash-quenched Re^{II} is able to oxidize F₃Y. Spectra of \bullet Y and the \bullet F₃Y were collected 50 ns after irradiating a solution of either [Re]–Y– β C19 (at pH 12) or [Re]–F₃Y– β C19 (at pH 8.3) in borate buffer and in the presence of 200 mol equiv of FQ. The spectra, which are reproduced in Figure S3, exhibit the expected isolated peaks for the \bullet F₃Y radical at $\lambda_{max} = 425$ nm and the \bullet Y radical at $\lambda_{max} = 412$ nm. We also observe that the \bullet F₃Y radical in Tris buffer shifts to $\lambda_{max} = 418$ nm.

The optimal FQ concentration was determined by titrating solutions of 50 μ M [Re]–F₃Y– β C19 with 5–1000 mol equiv of FQ. As Figure S4 shows, the best concentration of FQ was determined to be 20 mol equiv, which was the concentration used to perform all subsequent kinetic analysis involving the \bullet F₃Y radical. At 20 mol equiv of FQ, not all of the [Re^I]* is quenched, and thus the flash quench TA spectrum of [Re]– \bullet F₃Y– β C19 taken 25 ns after laser excitation ($\lambda_{exc} = 355$ nm) appears as a sum of the \bullet F₃Y and the remaining charge-separated state. Figure S5 shows the decay profile of the TA spectrum at $\lambda_{det} = 425$ nm. A fast time component of 100 ns corresponding to the recombination of the charge separated state is followed by a slower time component corresponding to the decay of the \bullet F₃Y radical produced by flash quenching. The TA spectral profile of the flash-quenched radical may be

spectrally isolated by delaying its detection (typically by 0.5–1 μ s) until after the decay of the charge-separated state. Figure 5a




Figure 5. (a) TA spectra and of [Re]-F₃Y-βC19 collected 500 ns (top), 5 μ s (middle) and 30 μ s (bottom) after a 7 ns 355 nm excitation pulse of laser light. (b) Lifetime decay of TA signal at 395 (○ [blue]), 410 (○ [green]), and 425 (○ [brown]) nm. The monoexponential fit is shown by the solid lines. The solution contained 50 μ M [Re]-F₃Y-βC19 with 20 equiv (1 mM) Ru(NH₃)₆Cl₃, 1 mM CDP, and 3 mM ATP, 15 mM MgSO₄ and 5% glycerol in 50 mM borate buffer (pH 8.3). Colored vertical bands (a) indicate the portion of the spectrum polled for recording the kinetic decays in (b).

shows the TA spectrum of a flash-quenched peptide 500 ns after laser excitation; the λ_{max} = 425 nm of F₃Y is clearly observed. The radical, monitored at 395, 410, and 425 nm, decays monoexponentially with lifetimes of τ_{395} = 14.7 ± 0.2 μ s, τ_{410} = 13.5 ± 0.2 μ s and τ_{425} = 14.5 ± 0.2 μ s, Figure 5b. In this optimized system, the photochemical yield of F₃Y formation is calculated to be 4.9% (see SI).

Two Conformations of [Re]-F₃Y-βC19 Bound to α2.

The relatively weak binding between [Re]-X-βC20 and α2 manifests in the dynamics of the peptide N-terminus, as we have shown previously.³¹ Crystallographic measurements of βC20 and α2 reveal the C-terminal 16 amino acids of the peptide, but the N-terminal four are not visible, suggesting that they are not held tightly to the protein surface.⁸ Both the [Re] and Y356 are located in this flexible region of the peptide, and when [Re]-X-βC19 is in the presence of α2, the lifetime of the [Re]^I* reports on the local environment of both the [Re] complex as well as the proximal fluorotyrosine. The decay signal from the [Re]^I*—in the presence of an amino acid that it cannot oxidize—is biexponential when the peptide is bound to the protein.³¹ The fast time decay, at 60 ns, is similar to [Re]^I* in solution (59 ns), and was assigned to an “off” state where the chromophore is largely solvated. A longer time decay, at 155 ns, was ascribed to the N-terminus binding closely to the surface of α2 in an “on” state, owing to occluding solvent from [Re].

The [Re]^I* lifetime measurements were repeated for the [Re]-X-βC19 peptide with nonoxidizable (X = F) and oxidizable (X = F₃Y) amino acids associated to each of the α2 mutants prepared here. All decays were biexponential; the lifetimes obtained from a fit of the lifetime decay of [Re]-F-βC19 are shown in Figure 6a. The “off” lifetime increases




Figure 6. Lifetime of [Re]^I* excited state of 10 μ M [Re]-X-βC19 for (a) X = F and (b) X = F₃Y peptide in the presence of α2 mutants at 20 μ M, in a solution of 1 mM CDP, 3 mM ATP, 15 mM MgSO₄, and 5% glycerol, in 50 mM borate (pH 8.3). For biexponential decays, the percentage contribution of short and long components to the decay is listed.

marginally from 52 to 60 ns, and the “on” lifetime of 180 ns is the same for all four mutant proteins. A biphasic decay for the [Re]-F₃Y-βC19 peptide bound to α2 is also obtained (Figure 6b), but with significantly attenuated lifetimes (“on” lifetime of 29 ns, “off” lifetime of 100 ns) owing to the quenching of [Re]^I* by F₃Y[•] as described above. The similarity of the percentage of the short and long lifetime components to the overall decay suggests similar binding conformations for both peptides. It is likely that all four states of the [Re]^I* (on/quenched, off/quenched, on/unquenched, off/unquenched) are present in solution.

[Re]-F₃Y-βC19 Lifetimes in the Presence of α2 Mutants. The emission lifetimes permit the formation of the F₃Y[•] to be monitored. Radical injection, however, requires that the F₃Y on the photopeptide in the presence of each α2 mutant be directly observed by TA spectroscopy. Figure S6 shows the spectra recorded at 1 μ s for the peptide alone, and in the presence of each protein. For the free peptide and for the Y731F mutant, for which radical injection is blocked, the typical spectrum of the F₃Y with λ_{max} = 425 nm is observed, with a small shoulder at 410 nm (Figure S6a); this spectral profile is typical of fluorotyrosyl radicals.³⁰ Figure S6b displays the TA spectrum of F₃Y in the presence of mutants that are theoretically capable of radical injection. The radical profile changes significantly. The λ_{max} = 425 nm broadens and a pronounced shoulder at λ_{max} = 400 nm appears; the spectrum of the C439S mutant shown in Figure 7a is representative. We chose to monitor kinetics at three wavelengths, 425, 410, and 395 nm, as these correspond to the λ_{max} of F₃Y, its typically observed shoulder, and the new, shifted shoulder that appears in the presence of the protein. For Y731F and Y730F, the TA signal decays monoexponentially at all wavelengths. In contrast, the signals for [Re]-F₃Y-βC19 in the presence of C439S and wt mutants decay biexponentially with a significantly shorter lifetime component. Figure 7b shows the decay of F₃Y for the C439S mutant; the residuals for the mono- and biexponential fits are shown in Figure S7. A summary of the lifetimes of the TA signal of F₃Y at the three different wavelengths for the free peptide and the peptide in the presence of Y731F-α2, Y730F-α2, C439S-α2 as well as the wt-α2 is plotted in Figure 8; a tabulation of these lifetimes and their amplitude components for the four systems is given in Table S1.




Figure 7. (a) TA spectra of [Re]-F₃Y-βC19 in the presence of C439S-α2 collected 1 μs (top), 15 μs (middle) and 30 μs (bottom) after a 7 ns 355 nm excitation pulse of laser light. (b) Lifetime decay of TA signal at 395 (○ [blue]), 410 (○ [green]), and 425 (○ [brown]) nm. The biexponential fit is shown by the solid lines. The solution contained 50 μM [Re]-F₃Y-βC19, 100 μM C439S-α2, 20 equiv (1 mM) Ru(NH₃)₆Cl₃, 1 mM CDP, and 3 mM ATP, 15 mM MgSO₄ and 5% glycerol in 50 mM borate buffer (pH 8.3). Colored vertical bands (a) indicate the portion of the spectrum polled for recording the kinetic decays in (b).




Figure 8. Lifetime of [Re]-F₃Y-βC19 peptide, and in the presence of the four α2 variants. Decay lifetimes of TA signal of F₃Y were observed at 395 (● [blue]), 410 (● [green]), and 425 (□ [brown]) nm. For the peptide in solution, in the presence of Y731F-α2, or Y730F-α2, there is no significant change in radical lifetime. With C439S-α2 and the wt-α2 subunit, the TA signal of F₃Y exhibits a biexponential decay owing to the contribution of a significantly shorter lifetime component arising from radical injection into the protein.

DISCUSSION

The unnatural tyrosine—2,3,6-trifluorotyrosine (F₃Y)—permits a photoRNRα2 to be constructed by binding [Re]-F₃Y-βC19 to α2. The F₃Y-photoRNRα2 construct provides three important features to enable the kinetics of radical initiation and propagation to be uncovered. First, Figure 3d establishes the pK_a of F₃Y, when incorporated into the full-length peptide, to be 7.1 ± 0.1. In order to generate proton-independent oxidation of the F₃Y by the [Re^I]^{*} (electron transfer only), the F₃Y must be in its deprotonated state. Thus, the proton-independent oxidation of F₃Y by [Re^I]^{*} may occur at a mild pH; we chose to perform spectroscopic experiments at pH 8.3 where F₃Y is ~94% deprotonated. Second, the reduction potential of F₃Y is ~180 mV above tyrosine at pH

8.3,¹³ thus providing a driving force for oxidation of the tyrosines of α2. Third, the absorption maximum of the F₃Y is sensitive to its local environment, shifting 7 nm by changing buffer identity in solution (Figure S3). This spectral shift allows F₃Y to be spectrally isolated, and the radical can be time-resolved at multiple wavelengths.

F₃Y Radical Photoinitiation. The F₃Y radical is generated efficiently by laser flash photolysis of [Re^I] incorporated within the [Re]-F₃Y-βC19 peptide. The TA spectrum of the photolyzed peptide in the presence of substrate, effector, and buffer establishes that the ³MLCT excited state of [Re], [Re^I]^{*}, is readily quenched by F₃Y⁻ to generate the intramolecular charge-separated state [Re(bpy^{•-})]-F₃Y-βC19. The absorption features characteristic of the charge transfer photoproducts, F₃Y and bpy^{•-}, are observed in the TA spectrum of Figure 4. These features decay concomitantly with one another, and they persist for a time longer than the [Re^I]^{*} excited state. Identical lifetimes for the charge-separated state were observed for each of the protein mutants prepared here.

In order to extend the lifetime of F₃Y and isolate its spectral signatures, radical photoinitiation was performed in the presence of the reversible flash-quench reagent Ru(NH₃)₆Cl₃. The Ru^{III} complex oxidatively quenches the [Re^I]^{*} within the laser pulse to furnish the [Re^{II}] ground state. [Re^{II}] is also thermodynamically competent for tyrosinate oxidation, subsequently regenerating the [Re^I] ground state and a free F₃Y. Since neither the [Re^I]^{*} nor the intramolecular charge-separated state are present upon flash quenching, the resulting TA features are solely representative of the radical. Spectra of F₃Y and Y under flash quench conditions clearly show disparate absorption maxima (Figure S3), which concur with those observed for tyrosyl radicals in the βC19 construct that were generated stoichiometrically with a benzophenone photooxidant.²³ In addition, we found that the λ_{max} of the F₃Y changes as a function of buffer composition, highlighting the sensitivity of the radical to its environment (Figure S3). There is an optimum concentration of the FQ reagent. High concentrations of FQ decrease the observed yield of radical because contaminating Ru^{II} (resulting from the flash quench process) is present at higher concentration in solution, which is able to reduce the photogenerated radical. Figure S4 shows that 20 mol equiv engenders the highest yield of radical with the longest observable lifetime.

Spectroscopy of [Re]-F₃Y-βC19 Bound to α2 Mutants. The equilibrium binding of [Re]-labeled peptides with the α2 subunit can be measured by fluorometric titration.³¹ However, in this case, the quenching of [Re] by the deprotonated F₃Y⁻ was so efficient that the emission intensity of [Re^I]^{*} was too low to provide a reliable measurement of the binding between the peptide and α2. Thus, we reverted to competitive inhibition assay measurements to reveal that K_D is 9 ± 1 μM. With this K_D, spectroscopic measurements employed a mixture of 50 μM peptide and 100 μM α2 to ensure that 86% of the peptide was bound to α2.

Even in this bound state, the N-terminus of the photopeptide resides in two states, one in which it is closely associated with the α2 subunit (“on”) and one in which it is largely solvent exposed (“off”).³¹ This on/off dynamic was measured by monitoring the emission lifetime of the [Re^I]^{*} for a control [Re]-F-βC19 peptide, Figure 6a. The lifetime of the solvent-exposed excited state is much shorter than when it is adsorbed to the protein surface. For the experiments reported here, we

also define this two-state dynamic for the fluorotyrosine-containing peptide bound to each of the point mutated $\alpha 2$ proteins. All constructs displayed the two-state behavior, as shown by Figure 6b. We note that the $[\text{Re}^{\text{I}}]^*$ lifetime of the $\text{F}_3\text{Y}-\beta\text{C19:Y731F-}\alpha 2$ construct corresponding to the “on” state ($\tau = 29$ ns) is unquenched relative to its lifetime in buffered solution ($\tau = 22$ ns). This observation confirms that the highly oxidizing $[\text{Re}^{\text{I}}]^*$ is unable to extract electrons from protein side chains via direct oxidation of tyrosine within the protein. Consistent with this observation, the “on” lifetime of the $[\text{Re}^{\text{I}}]^*$ is the same for all constructs (see Figure 6). Thus, the primary quenching pathway of the $[\text{Re}^{\text{I}}]^*$ is electron transfer solely from the adjacent F_3Y on the peptide.

The decay of $[\text{Re}^{\text{I}}]^*$ is accompanied by the appearance of absorption features characteristic of $\bullet\text{F}_3\text{Y}$ at $\lambda_{\text{max}} = 425$ nm in borate buffer and $\lambda_{\text{max}} = 418$ nm in an otherwise identical solution of the mildly more hydrophobic Tris buffer (Figure S3). The lifetime of the photogenerated $\bullet\text{F}_3\text{Y}$ is provided, independent of protein oxidation, by the $[\text{Re}]-\text{F}_3\text{Y}-\beta\text{C19:Y731F-}\alpha 2$ construct (Figure 1a). As summarized in Figure 8, the lifetime of the $\bullet\text{F}_3\text{Y}$ marginally depends upon the wavelength of observation ($\tau_{425} = 13.3 \pm 0.2 \mu\text{s}$, $\tau_{410} = 14.2 \pm 0.2 \mu\text{s}$, and $\tau_{395} = 16.5 \pm 0.4 \mu\text{s}$). At $\lambda_{\text{det}} = 425$ nm, this lifetime is slightly shorter than that observed for the free peptide in solution. The lifetime at $\lambda_{\text{det}} = 410$ nm matches the solution lifetime, and the lifetime at $\lambda_{\text{det}} = 395$ nm is longer than the lifetime when protein is not present. These lifetimes correspond to k_0 denoted in Figure 1. This heterogeneity suggests that the radical, whose spectral features are sensitive to local environment, may experience multiple conformations when in the presence of the unnatural phenylalanine on the surface of the protein. The local environment at Y356 does depend on the residue at 731 in the intact $\alpha 2:\beta 2$ system. The $\bullet\text{Y356}$ radical may be trapped when $\bullet\text{NO}_2\text{Y122}$ is introduced into $\beta 2$.¹⁹ The g_x value for trapped $\bullet\text{Y356}$ in $\text{Y731F-}\alpha 2$ (2.0073) is shifted relative to $\text{wt-}\alpha 2$ (2.0063). The g -value for $\bullet\text{Y}$ in proteins is known to vary between 2.006 and 2.009 as a function of local environment, with the lower values corresponding to tyrosyl radicals involved in hydrogen-bonding. This result implies that $\bullet\text{Y356}$ is involved in hydrogen-bonded stabilization in the wt enzyme, but not $\text{Y731F-}\alpha 2$. Together, these results suggest that the radical in the presence of Y731F experiences multiple solution/surface conformations. Of these different conformations, the amplitude of the monoexponential lifetime of $[\text{Re}^{\text{I}}]^*$ bound to F_3Y (Figure 6b) conveys that a significant portion of the peptide N -terminus (20–30%) is in the conformer of the “on” state. However, even in this conformation, $\bullet\text{F}_3\text{Y}$ cannot competently inject the radical into $\alpha 2$ owing to the phenylalanine block.

Radical Propagation into $\alpha 2$. With the ability to isolate the $\bullet\text{F}_3\text{Y}$ radical and temporally profile its lifetime in the absence of protein oxidation, the kinetics for radical transfer along the RNR pathway are revealed for the first time. The F point mutation was moved from position 731 to position 730 (Figure 1b), which would allow for the oxidation of Y731 but block any further transport of the radical into the $\alpha 2$ subunit. Photogeneration of $[\text{Re}]-\bullet\text{F}_3\text{Y}-\beta\text{C19}$ in the presence of $\text{Y730F-}\alpha 2$ again reveals monoexponential decays at the three wavelengths: 425 nm, $14.0 \pm 0.2 \mu\text{s}$; 410 nm, $13.7 \pm 0.2 \mu\text{s}$; 395 nm, $14.4 \pm 0.2 \mu\text{s}$. The lifetimes are all within error of one another, suggesting that the radical is in a homogeneous environment in the presence of the native Y731, to which it can hydrogen bond. A new spectral feature at 400 nm appears.

Since the spectral features of $\bullet\text{F}_3\text{Y}$ are sensitive to local environment, we assign this feature to the shoulder of the $\bullet\text{F}_3\text{Y}$ spectrum for those F_3Y that are hydrogen-bonded to Y731. This result suggests that the radical residing in the “on” conformation has a spectral signature that is shifted to higher energy relative to the free peptide or the dynamic Y731F radical. Though both “on” and “off” conformations are present, the observed lifetime of $\bullet\text{F}_3\text{Y}$ should be monoexponential as it corresponds to the sum of k_0 and k_1 (Figure 1b). Inasmuch as $(k_0 + k_1)$ of $[\text{Re}]-\text{F}_3\text{Y}-\beta\text{C19:Y730F-}\alpha 2$ is similar to k_0 of $[\text{Re}]-\text{F}_3\text{Y}-\beta\text{C19:Y731F-}\alpha 2$, we conclude that radical injection into the surface of the protein is blocked when the radical cannot further propagate along the pathway.

Consistent with this contention, dramatic changes occur when Y730 is present to propagate the radical into the subunit. As shown by the data in Figure 8, the rate of $[\text{Re}]-\bullet\text{F}_3\text{Y}-\beta\text{C19}$ decay increases significantly for both the C439S- $\alpha 2$ mutant and the wt enzyme. In each case, both Y730 and Y731 are present, and in each case the lifetimes at all wavelengths become biexponential. For C439S, in which a serine substitutes for the active site cysteine (Figure 1c) the TA signal at 395 nm consists of a long phase ($17.3 \pm 1.0 \mu\text{s}$, 81%) and a short phase ($2.2 \pm 1.4 \mu\text{s}$, 19%) (see Figure 7b). Similar pairs of lifetimes were observed for 410 and 425 nm, as shown in Table S1. The amplitudes of each signal can be used to assign each phase of decay to a conformation on the protein surface. As in the measurement of emission decay of the $[\text{Re}^{\text{I}}]^*$, the large amplitude component (80%) of the radical decay is attributed to the portion of the peptide that is largely solvated, in the “off” state. The small amplitude (20%) matches the “on” state. In this conformation, the $\bullet\text{F}_3\text{Y}$ lifetime is much shorter, indicating that it is able to oxidize Y731. Previous analysis of the crystal structure of $\text{wt-}\alpha 2$ concluded that there is hydrogen-bonding between Y731 and Y730.⁸ Since the installation of Y730F—a change of only one hydroxyl group from Y730—prevents oxidation of Y731 from occurring, we postulate that the enzyme has evolved to employ the hydrogen bonding between Y730 and Y731 (a Y–Y dyad) in proton-coupled tyrosine oxidation.

The “off” lifetime then serves as a baseline (k_0 , Figure 1c) for the rate of oxidation of Y–Y by $\bullet\text{F}_3\text{Y}$. Substituting the average across the three wavelengths for the lifetime of the radical in the “on” ($2.5 \pm 1.0 \mu\text{s}$) and “off” ($16.9 \pm 0.7 \mu\text{s}$) states into eq 1 yields a rate constant for radical injection of C439S- $\alpha 2$ to be $(4 \pm 2) \times 10^5 \text{ s}^{-1}$. This injection event is rate limited by the slower of k_1 and k_2 , Figure 1c. Since oxidation of Y731 is not possible without prearrangement with Y730, as shown in the $\text{Y730F-}\alpha 2$ mutant, we believe k_1 is the limiting step. A similar oxidation event is observed for the wt enzyme, which contains the active site cysteine. The averaged lifetimes for the long phase ($15.4 \pm 0.5 \mu\text{s}$) and the short phase ($3.0 \pm 1.4 \mu\text{s}$) of $\bullet\text{F}_3\text{Y}$ in $[\text{Re}]-\text{F}_3\text{Y}-\beta\text{C19:wt-}\alpha 2$ correlate to an injection rate of $(3 \pm 2) \times 10^5 \text{ s}^{-1}$. As in the C439S- $\alpha 2$ experiment, this rate constant corresponds to the rate-limiting step among k_1 , k_2 and k_3 , Figure 1d, and it is within error limit of the injection kinetics observed in $[\text{Re}]-\text{F}_3\text{Y}-\beta\text{C19:C439S-}\alpha 2$. The requirement of hydrogen-bonding between Y731 and Y730 again leads us to conclude that the rate-limiting oxidation for $[\text{Re}]-\text{F}_3\text{Y}-\beta\text{C19:wt-}\alpha 2$ is k_1 , Figure 1d.

The need for the Y–Y dyad to promote radical injection into $\alpha 2$ is consistent with the PCET reactivity of tyrosine in model compounds. The rate constant for oxidation of tyrosine depends dramatically on the proximity of a hydrogen-bonding

partner to the phenol.^{32–36} Specifically, in a series of phototriggered Ru^{II}(bpy)₃–Y model dyads, the addition of a carboxylate at the ortho position of the tyrosine phenol induces a hydrogen bond and increases the rate for PCET at pH 8 from 10⁴ s⁻¹ to 10⁵–10⁶ s⁻¹.³¹ The criticality of coupling oxidation to a hydrogen bond is further demonstrated by its ability to drive less favored reactions. For instance, a pair of Ru^{II}(bpy)₃–Y models containing benzimidazole hydrogen-bond partners were synthesized in which one congener contained³⁶ a 0.2 eV lower driving force but a 0.2 Å shorter hydrogen-bond distance. The shorter hydrogen bond drives the rate of oxidation by nearly 1 order of magnitude greater than for the congener with the greater thermodynamic driving force but longer hydrogen bond.³⁶ These observations for model tyrosyl radical systems are in line with the similarity of the observed radical kinetics of [Re]–F₃Y–βC19:Y731F-α2 and [Re]–F₃Y–βC19:Y730F-α2. In [Re]–F₃Y–βC19:Y730F-α2, a hydrogen bond to Y730 is absent, thus obviating PCET.

CONCLUSION

These results reported herein show that radical injection and propagation in RNR with any appreciable rate requires that both Y731 and Y730 be in place to establish the hydrogen-bonded network needed for PCET. With the Y–Y dyad present, we are able to generate and monitor a radical that can oxidize the residues on the α2 pathway for the first time. The rate for radical injection and transport in α2 is fast, on the order of 3 × 10⁵ s⁻¹. The ability to shut down this efficient PCET pathway for radical propagation by modifying the hydrogen-bonding network of the amino acids composing a colinear PCET pathway in α2 suggests a finely tuned evolutionary adaptation of RNR to control radical transport in this enzyme.

ASSOCIATED CONTENT

Supporting Information

Material vendors and abbreviations used; sequence of primers used in mutagenesis; full description of all tools and instruments; calculations of uncertainty; [Re]–F₃Y–βC19 emission quenching at pH 8.3; residuals of C439S and wt radical decays; numerical table of radical lifetimes. This material is available free of charge via the Internet at <http://pubs.acs.org>.

AUTHOR INFORMATION

Corresponding Author

nocera@mit.edu

ACKNOWLEDGMENTS

We gratefully acknowledge the National Institutes of Health (GM 47274, D.G.N.; GM 29595, J.S.) for provided funding to enable this research. P.G.H acknowledges a fellowship from the National Institutes of Health (GM 087034). We are grateful to Ellen C. Minnihan for her expertise and time.

REFERENCES

- (1) Nordlund, P.; Reichard, P. *Annu. Rev. Biochem.* **2006**, *75*, 681–706.
- (2) Stubbe, J.; van der Donk, W. A. *Chem. Rev.* **1998**, *98*, 705–762.
- (3) Seyedsayamdost, M. R.; Stubbe, J. *J. Am. Chem. Soc.* **2006**, *128*, 2522–2523.
- (4) Stubbe, J.; Nocera, D. G.; Yee, C. S.; Chang, M. C. Y. *Chem. Rev.* **2003**, *103*, 2167–2202.

- (5) Reece, S. Y.; Nocera, D. G. In *Quantum Tunneling in Enzyme Catalyzed Reactions*; Scrutton, N., Allemann, R., Eds.; Royal Society of Chemistry Press: London, 2009.
- (6) Reece, S. Y.; Hodgkiss, J. M.; Stubbe, J.; Nocera, D. G. *Philos. Trans. R. Soc., Ser. B* **2006**, *361*, 1351–1364.
- (7) Reece, S. Y.; Nocera, D. G. *Annu. Rev. Biochem.* **2009**, *78*, 673–699.
- (8) Uhlin, U.; Eklund, H. *Nature* **1994**, *370*, 533–539.
- (9) Nordlund, P.; Sjöberg, B.-M.; Eklund, H. *Nature* **1990**, *345*, 593–598.
- (10) Ekberg, M.; Sahlin, M.; Eriksson, M.; Sjöberg, B.-M. *J. Biol. Chem.* **1996**, *271*, 20655–20659.
- (11) Aberg, A.; Hahne, S.; Karlsson, M.; Larsson, A.; Ormö, M.; Ahlgren, A.; Sjöberg, B. M. *J. Biol. Chem.* **1989**, *264*, 12249–12252.
- (12) Larsson, A.; Sjöberg, B. M. *EMBO J.* **1986**, *5*, 2037–2040.
- (13) Seyedsayamdost, M. R.; Yee, C. S.; Reece, S. Y.; Nocera, D. G.; Stubbe, J. *J. Am. Chem. Soc.* **2006**, *128*, 1569–1579.
- (14) Seyedsayamdost, M. R.; Xie, J.; Chan, C. T. Y.; Schultz, P. G. *J. Am. Chem. Soc.* **2007**, *129*, 15060–15071.
- (15) Minnihan, E. C.; Seyedsayamdost, M. R.; Stubbe, J. *Biochemistry* **2009**, *48*, 12125–12132.
- (16) Minnihan, E. C.; Seyedsayamdost, M. R.; Uhlin, U.; Stubbe, J. *J. Am. Chem. Soc.* **2011**, *133*, 9430–9440.
- (17) Seyedsayamdost, M. R.; Chan, C. T. Y.; Mugnaini, V.; Stubbe, J.; Bennati, M. *J. Am. Chem. Soc.* **2007**, *129*, 15748–15749.
- (18) Yokoyama, K.; Uhlin, U.; Stubbe, J. *J. Am. Chem. Soc.* **2010**, *132*, 15368–15379.
- (19) Yokoyama, K.; Smith, A. A.; Corzilius, B.; Griffin, R. G.; Stubbe, J. *J. Am. Chem. Soc.* **2011**, *133*, 18420–18432.
- (20) Chang, M. C. Y.; Yee, C. S.; Stubbe, J.; Nocera, D. G. *Proc. Natl. Acad. Sci. U.S.A.* **2004**, *101*, 6882–6887.
- (21) Reece, S. Y.; Seyedsayamdost, M. R.; Stubbe, J.; Nocera, D. G. *J. Am. Chem. Soc.* **2007**, *129*, 13828–13830.
- (22) Climent, I.; Sjöberg, B. M.; Huang, C. Y. *Biochemistry* **1992**, *31*, 4801–4807.
- (23) Reece, S. Y.; Seyedsayamdost, M. R.; Stubbe, J.; Nocera, D. G. *J. Am. Chem. Soc.* **2007**, *129*, 8500–8509.
- (24) Kavakli, I. H.; Sancar, A. *Biochemistry* **2004**, *43*, 15103–15110.
- (25) Byrdin, M.; Villette, S.; Eker, A. P. M.; Brettel, K. *Biochemistry* **2007**, *46*, 10072–10077.
- (26) Seyedsayamdost, M. R.; Yee, C. S.; Stubbe, J. *Nat. Protoc.* **2007**, *2*, 1225–1235.
- (27) Thelander, L. *J. Biol. Chem.* **1973**, *248*, 4591–4601.
- (28) Novikov, E.; Stobiecka, A.; Boens, N. *J. Phys. Chem. A* **2000**, *104*, 5388–5395.
- (29) Harris, D. C. *Quantitative Chemical Analysis*, 6th ed.; W. H. Freeman: New York, 2003.
- (30) Reece, S. Y.; Seyedsayamdost, M. R.; Stubbe, J.; Nocera, D. G. *J. Am. Chem. Soc.* **2006**, *128*, 13654–13655.
- (31) Reece, S. Y.; Lutterman, D. A.; Seyedsayamdost, M. R.; Stubbe, J.; Nocera, D. G. *Biochemistry* **2009**, *48*, 5832–5838.
- (32) Irebo, T.; Johansson, O.; Hammarström, L. *J. Am. Chem. Soc.* **2008**, *130*, 9194–9195.
- (33) Irebo, T.; Reece, S. Y.; Sjödin, M.; Nocera, D. G.; Hammarström, L. *J. Am. Chem. Soc.* **2007**, *129*, 15462–15464.
- (34) Rhile, I. J.; Mayer, J. M. *J. Am. Chem. Soc.* **2004**, *126*, 12718–12719.
- (35) Markle, T. F.; Mayer, J. M. *Angew. Chem., Int. Ed.* **2008**, *47*, 738–740.
- (36) Zhang, M.-T.; Irebo, T.; Johansson, O.; Hammarström, L. *J. Am. Chem. Soc.* **2011**, *133*, 13224–13227.